Inquiry Basket
CAS No.:
Cat No.: BADC-00761
4.5 
DBCO-PEG4-vc-PAB-(PEG2)-Duocarmycin DM is a drug-linker conjugate for ADC by using Duocarmycin DM (a potent antitumor antibiotic), linked via DBCO-PEG4-vc-PAB-(PEG2).
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
DBCO-PEG4-vc-PAB-(PEG2)-Duocarmycin DM, a bioconjugation molecule utilized in targeted cancer therapies, presents a multitude of applications. Here are four key applications:
Targeted Drug Delivery: The utilization of DBCO-PEG4-vc-PAB-(PEG2)-Duocarmycin DM in targeted cancer therapies involves the conjugation of this bioconjugation molecule to antibodies that exhibit specificity towards cancer cells. This groundbreaking approach facilitates the precise delivery of duocarmycin, a potent cytotoxic agent, directly to tumor cells. By minimizing off-target effects and enhancing therapeutic efficacy, this innovative strategy heightens the selectivity and potency of cancer treatments, reshaping the landscape of targeted drug delivery with remarkable precision.
Preclinical Oncology Research: Within the realm of preclinical oncology research, this compound assumes a pivotal role in evaluating the effectiveness of antibody-drug conjugates (ADCs). Researchers leverage the unique properties of DBCO-PEG4-vc-PAB-(PEG2)-Duocarmycin DM to investigate the pharmacokinetics, biodistribution, and antitumor activity of experimental ADCs. These studies yield indispensable data essential for advancing ADC candidates into clinical trials, propelling forward groundbreaking advancements in the field of oncology research with profound insights.
Biochemical Assays: In the domain of biochemical assays, DBCO-PEG4-vc-PAB-(PEG2)-Duocarmycin DM serves as a cornerstone for monitoring the internalization and intracellular processing of ADCs. Leveraging the click chemistry potential of DBCO, researchers can seamlessly conjugate this molecule to a diverse range of biological targets, facilitating a deeper comprehension of the underlying mechanisms of action. These assays not only unravel the intricacies of biological processes but also aid in optimizing the design of ADCs to achieve enhanced therapeutic outcomes, pushing the boundaries of biochemical research with unparalleled precision.
Combination Therapy Research: Embarking on studies exploring combination therapies, researchers leverage the versatility of this molecule by conjugating it with other therapeutic agents. By merging targeted delivery with complementary treatments, novel synergistic strategies are devised to combat resistance mechanisms and amplify anti-cancer effects.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00811 | Duocarmycin DM free base | 1116745-06-2 | |
| BADC-00337 | Seco-Duocarmycin TM | 1142188-60-0 | |
| BADC-00223 | Duocarmycin A | 118292-34-5 | |
| BADC-00362 | Duocarmycin B1 | 124325-93-5 | |
| BADC-00341 | Seco-Duocarmycin SA | 152785-82-5 | |
| BADC-00605 | Duocarmycin TM | 157922-77-5 | |
| BADC-00332 | Seco-DuocarmycinCN | 1613286-54-6 | |
| BADC-00333 | Seco-DuocarmycinDMG | 1613286-55-7 | |
| BADC-00342 | Seco-Duocarmycin MA | 1613286-57-9 | |
| BADC-00609 | Duocarmycin MB | 1613286-58-0 |
DBCO-PEG4-vc-PAB-(PEG2)-Duocarmycin DM
Required fields are marked with *
DBCO-PEG4-vc-PAB-(PEG2)-Duocarmycin DM
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
